Membership of the Royal Colleges of Physicians (MRCP) Practice Exam

In a patient on long-term warfarin therapy, the coagulation factor most likely to be present at reduced activity is Factor VII. Warfarin acts as an anticoagulant by inhibiting the vitamin K epoxide reductase enzyme, which is essential for the synthesis of vitamin K-dependent clotting factors. These factors include Factors II (prothrombin), VII, IX, and X.

Factor VII has the shortest half-life among these vitamin K-dependent factors, approximately 6 hours. As warfarin therapy continues, the levels of Factor VII will decrease more rapidly than those of factors with longer half-lives, such as Factor II or Factor X, because they remain longer in circulation before being affected by the reduced vitamin K availability. This leads to a more significant decrease in Factor VII activity in patients on warfarin, contributing to the anticoagulant effect seen with this therapy.

The other factors listed, such as Factor V, Factor VIII, and Factor XII, are not vitamin K-dependent and are therefore not directly affected by warfarin in the same manner as Factor VII. Factor V is involved in the prothrombinase complex but does not require vitamin K for its synthesis. Factor VIII is part of the intrinsic pathway